An observational study in Acute Kidney Injury, sponsored by Zhejiang Provincial People's Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-04-22.
Sponsored by Zhejiang Provincial People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Acute Kidney Injury with a site in China — 46 open to participants now, 54 under way, 1 of them phase 3. Acute Kidney Injury · China.
Among the 168 studies in Acute Kidney Injury with a site in China, this one is the 31st largest by planned enrollment of the 105 observational ones that give a count, is one of 10 that started in 2025, is one of 105 observational ones, reaches primary completion later than 21 of the 53 other live ones, and was the 128th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →46 of the 168 studies in Acute Kidney Injury with a site in China are open now. Recruiting first, the newest first:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Jinling Hospital, China · Sites in China
Ages 18–75
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 3 · Phase 4 10
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 152 across the 63 interventional studies, 472 across the 105 observational. Of the 82 that completed or were terminated, 4 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 168 have an industry lead sponsor. The 10 most frequent:
Zhejiang Provincial People's Hospital is the lead sponsor of 62 studies on the registry; 42 are open to participants now.
Zhejiang Provincial People's Hospital has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
19 of the studies in Acute Kidney Injury with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07850947Second Affiliated Hospital, Zhejiang University, School of MedicineAn Observational Study of Percutaneous Glomerular Filtration Rate (TGFR) in the Early Warning of Contrast-induced Acute Kidney Injury During the Peri-examination Period of Emergency Enhanced CT | 2026-12 |
| NCT07672860Jinling Hospital, ChinaPerioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors | 2026-12 |
| NCT07602465Zhongda HospitalThe Impact of Blood Pressure Variability During the Induction and Surgical Periods on Postoperative Acute Kidney Injury | 2026-12-01 |
| NCT06939387Zhejiang Provincial People's HospitalDrug-induced Kidney Injury Model | 2026-12-30 |
| NCT04789733The Cleveland ClinicThe GUARDIAN Pilot Trial | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 168 studies in Acute Kidney Injury with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To establish the prediction model of renal dysfunction in patients with drug-induced renal injury and study the prognosis of different drug treatments
Drug-induced acute kidney injury
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with acute kidney injury caused by the use of nephrotoxic drugs
Other: Observational study, no intervention
Observational study, no intervention
Model performance metrics assessed by AUC-ROC, accuracy and F1-score using 10-fold cross-validation
The prognosis of renal function was evaluated by measuring creatinine and proteinuria by laboratory tests. Predict outcomes using machine learning methods. And the prediction effect of the prediction model was evaluated by AUC-ROC, F1, accuracy and other indicators.
Time frame: through study completion, an average of 6 months
The rate at which creatinine falls
Time frame: 7 days, 1 month, 3 months after treatment
Plan to share: No — We will publish relevant research papers, patient data is not appropriate for public disclosure
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 21 months is below that.
Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhejiang Provincial People's Hospital